ChemDiv, a fully Integrated Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA
ChemDiv is the recognized global leader in discovery chemistry with the industry’s largest, most diverse, and most pharmacologically-relevant commercial collection of individually crafted, lead-like, drug-like small molecules and building blocks.
Our computational, structural biology, synthetic and medicinal chemistry team follow current trends in modern structure-based discovery chemistry to add novel diverse and targeted compounds at the rate of 50,000 molecules per year.
Our customers can get access to a variety of pre-plated annotated libraries with bioactive compounds. Customization options are available for over 100 pre-designed targeted and focused sets. It tackling multiple targets, protein domains, pathways, cellular processes, etc. Representative examples of these biased compound libraries include modulators of numerous protein-protein interactions, stem cell differentiation, apoptosis, proteasome cascade including diverse ligases, autophagy, epigenetics machinery, cell cycle including quiescent cancer cells, motor proteins, mitochondrial homeostasis and cell energetic, viral targets, bacterial genome, protein folding machinery including scaffolding proteins and chaperones and many others. We have also assembled library screening sets for agrochemical, cosmetics and food industries reflective of the Generally Recognized As Safe (GRAS) concepts.
ChemDiv is a recognized global leader in drug discovery solutions. Over the past 29 years ChemDiv has delivered hundreds of leads, drug candidates and new drugs in the area of CNS, oncology, virology, inflammation, cardiometabolic and immunology, to pharma, biotech and academic partners around the globe.
Dr. Ivashchenko holds Doctor of Sciences (1982) and Professor (1988) degrees. He is the Distinguished Inventor of the Russian Federation (1984), the winner of the State Prize of the USSR (1983) and the Prize of the Council of Ministers of the USSR (1989).Dr. Ivashchenko is a world-recognized expert in the field of medicinal chemistry. He has been instrumental in advancing and supervising a series of studies on the development of innovative drugs for the treatment of cancer, hepatitis C, influenza, Alzheimer’s disease, schizophrenia and obesity. Many of these studies are currently at the clinical stage. Dr. Ivashchenko is a co-author of over 750 scientific publications and patents.Alex V. Ivashchenko (born March 24, 1945) is a founder and CSO of Chemical Diversity Research Institute (CDRI) of the Center of High Technologies “ChemRar” (Khimki, Moscow region), ChemDiv Inc. (USA), AllaChem LLC (USA), Avineuro Pharmaceuticals (USA).
Prior to joining ChemDiv, Mr. Demuth held the positions of General Manager at Integrated Genomics. He has a long track record in the management of new ventures including holding the position of CEO of Cerulean Enterprises. Mr. Demuth has a BSc in Psychology from the University of Iowa and was a co-founder of the internationally-recognized Chicago Teacher Academy for Mathematics and Science with the Nobel Laureate Physicist, Leon Lederman. He is the author of 13 scientific papers.
Prior to joining ChemDiv, Dr. Khvat held the positions of Senior Research Scientist at the Ukrainian Scientific Research Institute for Pharmacology and Therapy of Endocrine Disorders and Post-Doctoral Research Scientist at the University of Nottingham, UK. He has a nine year track-record in custom synthesis and spectroscopic investigations of organic compounds including completion of over fifty custom and medicinal chemistry projects with major pharmaceutical and biotech companies. Dr. Khvat has a Ph.D. in organic chemistry from Kharkov State University and is the author of 26 scientific papers and 20 patents.
Dr. Pushechnikov has over 15 years of research experience in academy and biotech industries as well as managerial experience from various contract research and manufacturing organizations. Dr. Pushechnikov has a background in chemical engineering and a PhD in synthetic organic chemistry, which allowed him to acquire broad practical experience in managing interdisciplinary projects with emphasis on chemical biology, medicinal chemistry and process research for pharmaceutical and biotech companies. His achievements related to various aspects of drug discovery process are reflected in 36 peer-reviewed publications and patents.
More than 15 years of industrial experience in drug discovery and R&D. Dr. R. Karapetian graduated from Moscow State University in 1998 and obtained his Ph.D. from the Institute of Physico-Chemical Biology, Moscow State University in 2001. As guest-scientist he was working at Max-Planck Institute of Molecular Genetic in Berlin, Germany. His research is published in several peer-reviewed scientific papers in international and Russian academic journals and presented at domestic and international conferences.
Dr. Karapetian joined ChemDiv, Inc in 2004. As Director of Biology the last 13 years Dr. Karapetian is responsible for execution and management of studies from early discovery to late preclinical and translational. Under his supervision as the CSO of AVIonco novel effective antiandrogen for treatment of castration-resistant prostate cancer was developed and successfully completed clinical phase I/II.
Principal strengths include good knowledge and hands-on experience in design, execution and management of studies from early discovery to late preclinical and translational:
— Discovery – in vitro assay development and validation, mechanism of action, high throughput screening, DMPK, in vivo efficacy.
— Preclinical – pharmacokinetics, toxicology, regulatory-enabling studies.
— Clinical – basic understanding of the workflow with Phase I/II first-in-man studies, proof-of-concept studies, BE/DDI studies.
Volodymyr Kysil obtained his Ph.D. degree in organic chemistry from Taras Shevchenko National University of Kyiv, Ukraine. Prior to joining ChemDiv team, he held the position of Senior Research Scientist – Group Leader in the Laboratory of Biologically Active Compounds at the same university. In 1995 he was awarded the Andrej Kiprianov Prize by the National Academy of Science of Ukraine for the series of publications “Synthesis and Reactivity of Isoindole and Isoquinoline Compounds”. Since 2002, he has worked at ChemDiv as a Senior Research Scientist and since 2012 – as a Director of Chemistry. Throughout his career his research interests have been focused on medicinal chemistry-oriented synthesis of heterocyclic compounds by means of novel synthetic methodologies including diversity-oriented synthesis such as multicomponent and domino reactions. His research work has appeared in 3 reviews and more than 100 papers and patents in the field of synthetic and medicinal chemistry.
20Y experience of CRO with the main focus on small molecule drug discovery. Obtained multiple collaborations on international market with Pharma, Biotech, Academia clients in screening chemical libraries, custom chemistry, integrated discovery projects. Demonstrated capability of building and managing several productive BD teams. Experiences in both start-up and established CRO/biotech companies.
Elena A. Bulanova, Ph.D.
Elena A. Bulanova is a Chief Scientific Officer for Cell Technologies at Chemdiv. She graduated from Moscow State University with summa cum laude, Faculty of Biology, Department of Virology. Elena Bulanova received her Ph.D. degree at Cancer Research Center, Moscow, at Jury Vasiliev’s lab, which is famous for the studies on cytoskeleton systems and cell’s migration mechanisms. She was a postdoctoral fellow at Northwestern University, Chicago, at Gary Borisy’s lab, recognized for the studies on actin filaments polymerization at the cell leading edge and discovery of tubulin. During her fellowship Elena completed the study on mechanisms of filopodia initiation by reorganisation of dendritic network, which received around thousand citations to date. She joined Chemdiv after her postdoc and shortly became the Head of HTS and Assay Development laboratory. Her group accomplished several metabolic, neurology and cancer projects in collaboration with Big Pharma. Elena gained experience in 3D bioprinting and regenerative medicine accepting the offer to lead the Cell Technologies laboratory in 3D Bioprinting Solutions. She was a visiting scientist at Cell Department of UCLouvain, Belgium and completed the project for bioprinting of functional vascularized mouse thyroid gland. As a result Elena A. Bulanova has an extensive experience in cell biology, drug discovery and 3D bioprinting. She is an invited speaker at annual conferences for drug discovery and 3D bioprinrting.
Elena is a Сandidate Master of underwater sport, AIDA judge.
Scientific Advisory Board
Alexander Ivachtchenko, Prof., DSc.
Founder of ChemDiv, Chief Scientific Officer, Founding Memeber of Scientific Advisory Board
Professor Ivachtchenko is the founder of ChemDiv, Chief Scientific Officer and the founding member of the Scientific Advisory Board. He is the recipient of multiple European awards in the field of heterocyclic chemistry and has earned the prestigious title of Honored Inventor of the Russian Federation. Professor Ivachtchenko has a PhD in Chemistry from the Institute of Chemical Industry, a DSc in Chemistry from Mendeleev University of Chemical Technology. He is the author of 4 text books, 173 scientific papers and 141 patent applications.
Michael Brownstein, Prof., M.D., Ph.D.
Scientific Advisor, Consultant
M.D., Ph.D. brings over thirty years of experience as a scientific leader in the fields of genetics, endocrinology, pharmacology and drug development. Dr. Brownstein earned his bachelor’s degree from Columbia University and completed his medical training at University of Chicago, where he received his M.D. and Ph.D. in pharmacology. Dr. Brownstein has held leadership positions at NIH as Chief of the Laboratory of Genetics, NIMH/NHGIR, where he led the Brain Molecular Anatomy Project and the Molecular Gene Collection Project. He subsequently directed the Functional Genomics Program at the Venter Institute. Dr. Brownstein serves on numerous scientific and policy advisory boards has authored more than 200 research publications, and has founded several successful companies. His contributions have been recognized with the Distinguished Service Award for Biomedical Research, the Arthur S. Flemming Award, and the E. Gelhorn Prize in Neurophysiology, among other honors.
Hugo Kubinyi, Prof., DSc.
Consultant, University of Heidelberg
Professor Kubinyi is a member of the SAB of ChemDiv and currently the Professor of Pharmaceutical Chemistry at the University of Heidelberg. He has previously held the Chair of The QSAR and Modeling Society was an IUPAC Fellow and has been a prominent member of the QSAR and Molecular Modeling Society for 40 years. For 35 years he was responsible for the Molecular Modeling, X-ray Crystallography and Drug Design groups at BASF Pharmaceuticals. Professor Kubinyi has a PhD in Biochemistry from the Max Planck Institute and is the author of 5 text books, 90 scientific papers.
Tudor Oprea, Prof., Ph.D., M.D.
Consultant, University of New Mexico
Professor Oprea is a member of the SAB of ChemDiv and is currently Professor and Chief of the Division of Bio-computing at the University of New Mexico, School of Medicine in Albuquerque. Previously he was founder of Sunset Molecular Discovery LLC (SMDL), spent six years with AstraZeneca in Sweden and completed a successful academic tenure at the West University of Timisoara, Romania (1996-2003). Professor Oprea has an MD in general medicine and a PhD in molecular physiology from the “Victor Babes” University of Medicine and Pharmacy in Timisoara, Romania. He is the author or co-author of 13 book chapters, 43 scientific papers and 1 patent application.
Y. Yamamoto, Prof., DSc.
Consultant, Tohoku University
Professor Yamomoto is a member of the SAB of ChemDiv. His major research interests include the development of new synthetic reactions using organometallic reagents and catalysts, natural product synthesis and medicinal chemistry, and asymmetric & stereoselective syntheses. Professor Yamomoto is the recipient of the Chemical Society of Japan Award (1996), and the Humboldt Research Award (2002).